A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERR gamma ), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer.
Singh, T.D., Song, J., Kim, J., Chin, J., Ji, H.D., Lee, J.E., Lee, S.B., Yoon, H., Yu, J.H., Kim, S.K., Yoon, G.S., Hwang, H., Lee, H.W., Oh, J.M., Lee, S.W., Lee, J., Choi, H.S., Na, S.Y., Choi, W.I., Park, Y.J., Song, Y.S., Kim, Y.A., Lee, I.K., Cho, S.J., Jeon, Y.H.(2019) Clin Cancer Res 25: 5069-5081
- PubMed: 31010838 
- DOI: https://doi.org/10.1158/1078-0432.CCR-18-3007
- Primary Citation of Related Structures:  
5YSO - PubMed Abstract: 
New strategies to restore sodium iodide symporter (NIS) expression and function in radioiodine therapy-refractive anaplastic thyroid cancers (ATCs) are urgently required. Recently, we reported the regulatory role of estrogen-related receptor gamma (ERRγ) in ATC cell NIS function. Herein, we identified DN200434 as a highly potent (functional IC 50 = 0.006 μmol/L), selective, and orally available ERRγ inverse agonist for NIS enhancement in ATC.
Organizational Affiliation: 
Department of Medical Oncology Laboratory, All India Institute of Medical Sciences (AIIMS), New Delhi, India.